covid 19 vaccine

1. Oxford COVID-19 vaccine begins
human trial stage
d

2. University’s Jenner Institute who began
trials in humans last week jointly with
the University’s Oxford Vaccine Group.

3. 20 MILLION GOVERNMENT FUNDING
FOR OXFORD UNIVERSITY’S VACCINE
RESEARCH AND SUPPORT FOR THE
INSTITUTION’S CLINICAL TRIALS.

4. OXFORD’S WORLD-CLASS EXPERTISE IN VACCINOL
GLOBAL DEVELOPMENT, MANUFACTURING AND

5. THE POTENTIAL VACCINE ENTERED PHASE I
CLINICAL TRIALS LAST WEEK TO STUDY
SAFETY AND EFFICACY IN HEALTHY
VOLUNTEERS AGED 18 TO 55 YEARS

6. OV-19 DEVELOPED AT THE UNIVERSITY OF OXFOR
D WORKING WITH THE OXFORD VACCINE GROUP
A VIRAL VECTOR BASED ON A WEAKENED VERSIO
D (ADENOVIRUS) CONTAINING THE GENETIC MAT
PIKE PROTEIN. AFTER VACCINATION, THE SURFACE
ODUCED, WHICH PRIMES THE IMMUNE SYSTEM T

7. ANT ADENOVIRUS VECTOR (CHADOX1) WAS CHOS
ONG IMMUNE RESPONSE FROM A SINGLE DOSE
G, SO CANNOT CAUSE AN ONGOING INFECTION I
DIVIDUAL. VACCINES MADE FROM THE CHADOX1
N TO MORE THAN 320 PEOPLE TO DATE AND HAV